Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-0500
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report ; volume:8 ; number:1 ; day:23 ; month:4 ; year:2015 ; pages:1-5 ; date:12.2015
BMC Research Notes / Biomed Central; 8, Heft 1 (23.4.2015), 1-5, 12.2015
- Creator
-
Fukuizumi, Aya
Miyanaga, Akihiko
Seike, Masahiro
Kato, Yasuhiro
Nakamichi, Shinji
Chubachi, Kumi
Matsumoto, Masaru
Noro, Rintaro
Minegishi, Yuji
Kunugi, Shinobu
Kubota, Kaoru
Gemma, Akihiko
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13104-015-1126-8
- URN
-
urn:nbn:de:101:1-2021082206245222380280
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fukuizumi, Aya
- Miyanaga, Akihiko
- Seike, Masahiro
- Kato, Yasuhiro
- Nakamichi, Shinji
- Chubachi, Kumi
- Matsumoto, Masaru
- Noro, Rintaro
- Minegishi, Yuji
- Kunugi, Shinobu
- Kubota, Kaoru
- Gemma, Akihiko
- SpringerLink (Online service)
Other Objects (12)
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma